Drug intelligence / Profile preview

RAK cells

Development stage: Phase 2
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: Cell Therapies, Vaccines & Immunotherapeutics
Administration: Intravenous

Overview

RAK (RetroNectin activate killer) cells are an autologous cell immunotherapy derived from a patient's own peripheral blood mononuclear cells (PBMCs). These cells are induced ex vivo using RetroNectin together with anti-CD3 monoclonal antibody and Interleukin-2 (IL-2). RAK cells represent a heterogeneous population of cytotoxic effector cells, primarily composed of CD8+ T cells and natural killer T (NKT) cells, which possess a broad spectrum of anti-tumor activity. The therapy involves collecting blood from patients, processing the cells in a laboratory to enhance their cancer-fighting abilities, and then reinfusing them back into the patient.

Other names: RetroNectin activate killer cells

Beyond the preview

Go deeper on RAK cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAK cells.

Explore the full profile